Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy. 2002

Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
Rouen University Medical School, Rouen, France.

BACKGROUND In patients with congestive heart failure (CHF) receiving ACE inhibitors, acute administration of selective endothelin (ET) antagonists additionally improves systemic and cardiac hemodynamics. We investigated, in a rat model of CHF, whether such acute synergistic effects are sustained and accompanied, in the long term, by an additional limitation of left ventricular remodeling or an increase in survival. RESULTS Rats were subjected to coronary artery ligation and treated for 3 or 9 months with vehicle or with the ACE inhibitor trandolapril (Tr) (0.3 mg/kg(-1) per day(-1)), the ET(A) antagonist LU 135252 (LU, 30 mg/kg(-1) per day(-1)), or their combination starting 7 days after ligation. After 3 months, the combination decreased LV systolic- and end-diastolic pressures (-32% and -80%, respectively) more markedly than Tr (-21% and -61%, respectively) or LU alone (-14% and -48%, respectively). Echocardiographic studies revealed that all treatments limited LV dilatation and increased LV fractional shortening and cardiac index. All treatments equally reduced left ventricular collagen density, whereas only Tr or the combination reduced LV weight. Finally, although LU did not modify long-term survival, Tr and the combination of Tr with LU induced a similar improvement of survival. CONCLUSIONS In this rat model, long-term combined administration of an ET(A) antagonist and an ACE inhibitor induces additional effects in terms of systemic and cardiac hemodynamics; however, this is not associated with an additional increase in long-term survival.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008026 Ligation Application of a ligature to tie a vessel or strangulate a part. Ligature,Ligations,Ligatures
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010666 Phenylpropionates Derivatives of 3-phenylpropionic acid, including its salts and esters.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
October 2002, Journal of cardiovascular pharmacology,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
March 1998, Hypertension (Dallas, Tex. : 1979),
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
June 2001, Acta pharmacologica Sinica,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
October 2002, Journal of cardiovascular pharmacology,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
March 1997, Circulation,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
December 1998, Journal of cardiac failure,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
August 2007, British journal of pharmacology,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
November 1992, European heart journal,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
August 1998, Cardiovascular research,
Paul Mulder, and Houssaine Boujedaini, and Vincent Richard, and Jean-Paul Henry, and Sylvanie Renet, and Klaus Münter, and Christian Thuillez
October 1994, Journal of cardiovascular risk,
Copied contents to your clipboard!